Clinical Edge Journal Scan

Tofacitinib more effective than tocilizumab in bDMARD-naïve patients with methotrexate-refractory RA


 

Key clinical point: Tofacitinib vs. tocilizumab was more likely to induce and maintain improvement in clinical disease activity index (CDAI) and remission during the first 12 months of therapy in biological disease-modifying antirheumatic drugs (bDMARD)-naïve patients with methotrexate-refractory rheumatoid arthritis (RA).

Major finding: Likelihood of achieving and maintaining 85% or more (adjusted odds ratio [aOR], 3.88; P less than .001), 70% or more (aOR, 2.89; P = .003) improvement in CDAI, and remission (aOR, 3.31; P less than .001) in the first 12 months was higher with tofacitinib vs. tocilizumab in bDMARD-naïve patients but not in patients with previous bDMARD failure.

Study details: This was a multicenter cohort study of 464 patients with methotrexate-refractory RA who had high to moderate CDAI and initiated treatment with tofacitinib (n=247) or tocilizumab (n=217).

Disclosures: This study was supported by research funds from the National Hospital Organization, Japan. The authors including the leading author reported receiving lecture fees from various sources.

Source: Mori S et al. RMD Open. 2021 May 6. doi: 10.1136/rmdopen-2021-001601 .

Recommended Reading

Mast cells may impact joint destruction through gene expression
MDedge Rheumatology
Switch to subcutaneous methotrexate curbs RA disease activity and increases quality of life
MDedge Rheumatology
Lower SARS-CoV-2 vaccine responses seen in patients with immune-mediated inflammatory diseases
MDedge Rheumatology
Nintedanib slows interstitial lung disease in RA patients
MDedge Rheumatology
Gene variant confirmed as strong predictor of lung disease in RA
MDedge Rheumatology
Secondhand smoke in childhood and adulthood linked to increased risk of rheumatoid arthritis
MDedge Rheumatology
Patients with RA on rituximab at risk for worse COVID-19 outcomes
MDedge Rheumatology
Novel study links air pollution to increased risk of rheumatoid arthritis flares
MDedge Rheumatology
RA: ARCTIC REWIND findings do not support csDMARD dose tapering among patients in remission
MDedge Rheumatology
RA: Three doses of intravenous tranexamic acid more effective than single dose post-TKA
MDedge Rheumatology